James Sillibourne

James Sillibourne is a Senior Director at Autolus Ltd., with extensive experience in Synthetic Genomics. Prior to their current role, James worked as a Research Scientist at Autolus, focusing on the development of CAR T-cell therapies for cancer treatment. Before joining Autolus, James served as a Post-doctoral Researcher at CEA and as a Postdoctoral Researcher at both Institut Curie and University of Massachusetts Medical School. James holds a Ph.D. in Molecular Pathology from the University of Dundee and a Bachelor's Degree in Biochemistry from Royal Holloway, University of London.